Brief: Immunovia Receives Final Medicare Payment Rate For Pancreasure Test
26/11/2025 15:24
Nov 26 (Reuters) - Immunovia AB (publ) IMMNOV.ST: RECEIVES FINAL MEDICARE PAYMENT RATE FOR PANCREASURE TEST CMS HAS FINALIZED A NATIONAL PAYMENT RATE OF $897 FOR PANCREASURE TEST EFFECTIVE JAN 1, 2026, THIS REPRESENTS SECOND OF THREE STEPS ON PATH TO MEDICARE REIMBURSEMENT Source text: ID:nMFN7bD5Gd Further company coverage: IMMNOV.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Immunovia AB (publ)
See all newsBrief: Immunovia Publishes Data On Pancreasure In Hereditary, Familial High-Risk Individuals
Brief: Immunovia To Carry Out Rights Issue Of About SEK 63 Million
Sweden's Immunovia Q2 sales rise on PancreaSure test uptake
Brief: Immunovia Reports Q2 Operating Loss Of SEK 22.8 Million
Brief: PancreaSure Achieves 88% Sensitivity In Immunovia Study